Fortress Biotech, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
FBIO Nasdaq 2840 www.fortressbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fortress Biotech, Inc.

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - May 14th, 2026 2:10 pm
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - May 13th, 2026 2:01 pm
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 - May 6th, 2026 2:01 pm
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - May 4th, 2026 6:30 am
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ - Apr 21st, 2026 6:30 am
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - Mar 31st, 2026 2:05 pm
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Mar 30th, 2026 2:05 pm
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - Mar 25th, 2026 2:01 pm
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - Mar 18th, 2026 6:30 am
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Feb 24th, 2026 6:53 am
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Feb 23rd, 2026 7:24 am
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Feb 23rd, 2026 6:30 am
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - Feb 23rd, 2026 6:00 am
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Jan 18th, 2026 5:51 am
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - Jan 13th, 2026 5:45 am
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - Dec 15th, 2025 6:00 am
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - Dec 10th, 2025 6:30 am
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates - Nov 14th, 2025 7:40 am
Fortress Biotech: Q3 Earnings Snapshot - Nov 14th, 2025 6:40 am
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Nov 14th, 2025 6:30 am